Teva Pharmaceutical Industries Limited (NYSE:TEVA) Receives Average Recommendation of “Hold” from Analysts

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) have been given an average rating of “Hold” by the eight analysts that are currently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $10.14.

TEVA has been the topic of several recent analyst reports. Evercore ISI raised shares of Teva Pharmaceutical Industries from an “in-line” rating to an “outperform” rating in a research report on Thursday, May 18th. UBS Group raised shares of Teva Pharmaceutical Industries from a “sell” rating to a “neutral” rating and increased their price objective for the company from $7.00 to $8.00 in a research report on Thursday, July 6th. Morgan Stanley initiated coverage on shares of Teva Pharmaceutical Industries in a research report on Thursday, May 25th. They set an “equal weight” rating and a $10.00 price objective on the stock. Finally, StockNews.com initiated coverage on shares of Teva Pharmaceutical Industries in a research report on Thursday, August 17th. They set a “buy” rating on the stock.

Teva Pharmaceutical Industries Stock Up 0.7 %

NYSE:TEVA opened at $9.76 on Friday. The firm’s 50-day moving average price is $8.74 and its 200-day moving average price is $8.66. The company has a market capitalization of $10.94 billion, a PE ratio of -4.88, a P/E/G ratio of 1.58 and a beta of 1.20. The company has a debt-to-equity ratio of 2.43, a current ratio of 1.02 and a quick ratio of 0.67. Teva Pharmaceutical Industries has a 1-year low of $7.09 and a 1-year high of $11.44.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Wednesday, August 2nd. The company reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.52 by $0.02. The firm had revenue of $3.88 billion for the quarter, compared to the consensus estimate of $3.69 billion. Teva Pharmaceutical Industries had a negative net margin of 14.87% and a positive return on equity of 27.93%. On average, equities analysts predict that Teva Pharmaceutical Industries will post 2.16 EPS for the current fiscal year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, CFO Eliyahu Sharon Kalif sold 35,125 shares of the company’s stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $9.73, for a total transaction of $341,766.25. Following the transaction, the chief financial officer now owns 99,162 shares in the company, valued at approximately $964,846.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other Teva Pharmaceutical Industries news, CFO Eliyahu Sharon Kalif sold 35,125 shares of the company’s stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $9.73, for a total transaction of $341,766.25. Following the transaction, the chief financial officer now owns 99,162 shares in the company, valued at approximately $964,846.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Eric A. Hughes sold 52,742 shares of the stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $8.30, for a total transaction of $437,758.60. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 89,848 shares of company stock worth $799,176. Company insiders own 0.62% of the company’s stock.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Several institutional investors have recently made changes to their positions in TEVA. Tobam bought a new position in shares of Teva Pharmaceutical Industries in the 2nd quarter worth approximately $25,000. Money Concepts Capital Corp bought a new position in shares of Teva Pharmaceutical Industries in the 4th quarter worth approximately $25,000. International Assets Investment Management LLC bought a new position in shares of Teva Pharmaceutical Industries in the 1st quarter worth approximately $26,000. Toronto Dominion Bank purchased a new stake in Teva Pharmaceutical Industries in the 4th quarter worth approximately $31,000. Finally, Spire Wealth Management increased its holdings in Teva Pharmaceutical Industries by 49.8% in the 1st quarter. Spire Wealth Management now owns 4,209 shares of the company’s stock worth $37,000 after acquiring an additional 1,400 shares in the last quarter. Institutional investors own 43.23% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams.